| abstract |
The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulation includes a galactomannan (eg, guar or hydroxypropyl guar) and a borate source (eg, boric acid). The formulation further comprises a cis-diol, such as sorbitol, which prevents galactomannan and borate crosslinking. Optionally, the formulation is substantially free of divalent cations (eg, magnesium, zinc and calcium). |